Crinetics Pharmaceuticals, Inc. (CRNX)
Pre-market:
| Previous close | 51.78 |
| Open | 51.87 |
| Bid | 53.07 x 200 |
| Ask | 53.17 x 200 |
| Day's range | 51.53 - 53.62 |
| 52-week range | 25.75 - 55.78 |
| Volume | |
| Avg. volume | 684,385 |
| Market cap | 4.784B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
Despite increased losses and expenses, Crinetics Pharmaceuticals Inc (CRNX) showcases promising clinical progress and a robust financial position to support future growth.
- GuruFocus.com
Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Over the past year, Stephen Betz has sold a total of 40,035 shares of the company and has not made any purchases. The insider transaction history for Crinetics Pharmaceuticals Inc shows a trend with 37 insider sells and no insider buys over the past year.
- Insider Monkey
Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now
We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against the other mid-cap healthcare stocks. Global Healthcare Market: Growth Projections, Challenges, and Tech-Driven Innovations According to projections by ReportLinker, the market for healthcare […]
